Literature DB >> 16009130

A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint.

Gabor Rohaly1, Jan Chemnitz, Silke Dehde, Alejandro Mena Nunez, Jochen Heukeshoven, Wolfgang Deppert, Irena Dornreiter.   

Abstract

The archetypal human tumor suppressor p53 is considered to have unique transactivation properties. The assumption is based on the fact that additionally identified human p53 isoforms lack transcriptional activity. However, we provide evidence for the existence of an alternatively spliced p53 isoform (Deltap53) that exerts its transcriptional activity independent from p53. In contrast to p53, Deltap53 transactivates the endogenous p21 and 14-3-3sigma but not the mdm2, bax, and PIG3 promoter. Cell cycle studies showed that Deltap53 displays its differential transcriptional activity only in damaged S phase cells. Upon activation of the ATR-intra-S phase checkpoint, Deltap53, but not p53, transactivates the Cdk inhibitor p21. Induction of p21 results in downregulation of cyclin A-Cdk activity and accordingly attenuation of S phase progression. Data demonstrate that the Deltap53-p21-cyclin A-Cdk pathway is crucial to facilitate uncoupling of repair and replication events, indicating that Deltap53 is an essential element of the ATR-intra-S phase checkpoint.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16009130     DOI: 10.1016/j.cell.2005.04.032

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  48 in total

1.  An indirect role for ASPP1 in limiting p53-dependent p21 expression and cellular senescence.

Authors:  Arnaud M Vigneron; Karen H Vousden
Journal:  EMBO J       Date:  2011-11-08       Impact factor: 11.598

2.  Splicing of mouse p53 pre-mRNA does not always follow the "first come, first served" principle and may be influenced by cisplatin treatment and serum starvation.

Authors:  Min Yang; Jack Wu; Si-Hung Wu; An-Ding Bi; D Joshua Liao
Journal:  Mol Biol Rep       Date:  2012-06-28       Impact factor: 2.316

3.  Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence.

Authors:  Y Tang; I Horikawa; M Ajiro; A I Robles; K Fujita; A M Mondal; J K Stauffer; Z-M Zheng; C C Harris
Journal:  Oncogene       Date:  2012-07-09       Impact factor: 9.867

Review 4.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

Review 5.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

6.  The MDM2 ubiquitination signal in the DNA-binding domain of p53 forms a docking site for calcium calmodulin kinase superfamily members.

Authors:  Ashley L Craig; Jennifer A Chrystal; Jennifer A Fraser; Nathalie Sphyris; Yao Lin; Ben J Harrison; Mary T Scott; Irena Dornreiter; Ted R Hupp
Journal:  Mol Cell Biol       Date:  2007-03-05       Impact factor: 4.272

7.  Repression of mammary stem/progenitor cells by p53 is mediated by Notch and separable from apoptotic activity.

Authors:  Luwei Tao; Amy L Roberts; Karen A Dunphy; Carol Bigelow; Haoheng Yan; D Joseph Jerry
Journal:  Stem Cells       Date:  2011-01       Impact factor: 6.277

8.  Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system.

Authors:  Kasandra J-L Riley; Laura A Cassiday; Akash Kumar; L James Maher
Journal:  RNA       Date:  2006-04       Impact factor: 4.942

9.  p53 suppresses CCL2-induced subcutaneous tumor xenograft.

Authors:  Xiaoren Tang; Salomon Amar
Journal:  Tumour Biol       Date:  2014-12-11

10.  Functional repeats (TGYCC)n in the p53-inducible gene 3 (PIG3) promoter and susceptibility to squamous cell carcinoma of the head and neck.

Authors:  Xiaoxiang Guan; Zhensheng Liu; Luo Wang; Li-E Wang; Erich M Sturgis; Qingyi Wei
Journal:  Carcinogenesis       Date:  2012-12-14       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.